Overview
Celon Pharma is an integrated pharmaceutical company conducting advanced scientific research and manufacturing modern medicines. The company also markets its own pharmaceutical products.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 18.88
- High
- PLN 19.28
- Low
- PLN 18.84
- Volume
- 7.77K
- Avg. vol.
- 10.89K
- Market cap
- PLN 1.02B
- P/E ratio
- 9.26
- EPS
- PLN 2.05
- Shares outstanding
- 53.91M
- 52-week
- PLN 18.00 – 19.40
- Dividend yield
- 0.42%
- Dividend
- PLN 0.08
- Ex dividend date
- Jun 27, 2024
- ISIN
- PLCLNPH00015
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 16.23m | USD -2.56m | USD -8.26m |
| Q1 2026 | USD 16.71m | USD -1.61m | USD 43.92m |
| Q4 2025 | USD 16.16m | USD 634.61k | USD -6.25m |
| Q3 2025 | USD 18.60m | USD 2.02m | USD 919.89k |
Results for Q3 2026:Nov 18, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2002-06-25. Active
34 2490 0005 0000 4600 2114 3292
06 1050 1025 1000 0090 8185 0118- 17 1050 1025 1000 0090 8183 5176
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
57 public aid cases recorded, with a total value of $144,110,691.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 23, 2026 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych | |
| Jun 22, 2026 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych | |
| Jun 22, 2026 | Aid for research and development projects: fundamental research | –– | Prezes Agencji Badań Medycznych |
Tenders
No recorded participation in tenders.
Trademarks
Celon Pharma holds 21 active trademarks registered with the Polish Patent Office. 8 marks have expired or were not registered. The first mark was filed in 2002.
| Mark | Protected until | |
|---|---|---|
| REDUZEK(word) | Sep 12, 2034 | |
| Pixara(word) | Jan 19, 2034 | |
| Zarixa(word) | Jun 24, 2032 | |
| Rivaxa(word) | Jun 24, 2032 | |
| BIRAZEK(word) | Apr 17, 2030 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
President of the Management Board independently; two members of the management board jointly; one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Action for Development of Researchsp. z o.o. | 342,206.92 USD | 73.2813% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Zakłady Farmaceutyczne PolpharmaS.A. | $780,704,907.94 | polpharma.pl | ||
| Adamed PharmaS.A. | $541,927,181.76 | adamed.com.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-10 | PKD change (Removed: 46.75.Z, 72.11.Z, 72.19; Added: 46.85.B, 72.10.Z) | |
| 2024-11-29 | Share capital change (5,375,650.00 PLN → 5,385,650.00 PLN) | |
| 2024-08-06 | Share capital change (5,105,650.00 PLN → 5,375,650.00 PLN) | |
| 2023-08-18 | Share capital change (5,103,500.00 PLN → 5,105,650.00 PLN) | |
| 2022-10-17 | Share capital change (5,103,000.00 PLN → 5,103,500.00 PLN) |
FAQ
Last updated: 2026-09-22